Literature DB >> 3898868

Regulation of plasma vasopressin in insulin-dependent diabetes mellitus.

R L Zerbe, F Vinicor, G L Robertson.   

Abstract

Patients with uncontrolled insulin-dependent diabetes mellitus have elevations in plasma vasopressin that cannot be accounted for totally by recognized osmotic or nonosmotic stimuli. To investigate the possibility that regulation of vasopressin secretion is abnormal in this disease, we characterized the vasopressin response to osmotic and hemodynamic stimuli in five uncomplicated, well-controlled insulin-dependent diabetics, and compared the results with those found in nondiabetic volunteers. During osmotic stimulation with hypertonic saline, plasma vasopressin increased in close linear correlation with plasma osmolality or sodium in both groups. However, in the diabetics, the lines describing the relationships between plasma sodium and vasopressin were shifted significantly to the left of normal, suggesting resetting of the osmostat. This shift was not due to abnormal stimulation by hyperglycemia, because increasing plasma glucose and osmolality by intravenous infusion of hypertonic dextrose produced no increase in plasma vasopressin in diabetics or normals. Tilt tests produced a slightly exaggerated increase in plasma vasopressin in diabetics, but their basal and upright pulse rate, blood pressure, plasma renin activity, norepinephrine, and hematocrit were all normal. The results indicate that in diabetic patients the osmoreceptor for osmotic regulation of vasopressin secretion is reset in such a way that higher plasma vasopressin levels are observed at comparable levels of plasma sodium. The exact cause and consequence of this abnormality remain to be determined.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3898868     DOI: 10.1152/ajpendo.1985.249.3.E317

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

Review 1.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

Review 2.  The endocrine system in diabetes mellitus.

Authors:  Hisham Alrefai; Hisham Allababidi; Shiri Levy; Joseph Levy
Journal:  Endocrine       Date:  2002-07       Impact factor: 3.633

3.  Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats.

Authors:  P Bardoux; H Martin; M Ahloulay; F Schmitt; N Bouby; M M Trinh-Trang-Tan; L Bankir
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

4.  Elevated copeptin, arterial stiffness, and elevated albumin excretion in adolescents with type 1 diabetes.

Authors:  Pattara Wiromrat; Petter Bjornstad; Carissa Vinovskis; Linh T Chung; Carlos Roncal; Laura Pyle; Miguel A Lanaspa; Richard J Johnson; David Z Cherney; Tyler K Reznick-Lipina; Franziska Bishop; David M Maahs; Raj Paul Wadwa
Journal:  Pediatr Diabetes       Date:  2019-08-29       Impact factor: 4.866

5.  Peripheral Insulin Resistance Is Associated with Copeptin in Patients with Chronic Kidney Disease.

Authors:  Juan Pablo Arroyo; Elvis A Akwo; Andrew S Terker; Aseel Alsouqi; Gautam Bhave; Raymond C Harris; Adriana M Hung; T Alp Ikizler
Journal:  Kidney360       Date:  2021-07-08

6.  Inhibition of mTOR activity in diabetes mellitus reduces proteinuria but not renal accumulation of hyaluronan.

Authors:  Sara Stridh; Fredrik Palm; Tomoko Takahashi; Mayumi Ikegami-Kawai; Peter Hansell
Journal:  Ups J Med Sci       Date:  2015-07-14       Impact factor: 2.384

7.  Hydration and kidney health.

Authors:  Nadine Bouby; William F Clark; Ronan Roussel; Christopher Taveau; Connie J Wang
Journal:  Obes Facts       Date:  2014-04-04       Impact factor: 3.942

Review 8.  Novel Cardiovascular Risk Factors in Patients with Diabetic Kidney Disease.

Authors:  Christodoula Kourtidou; Maria Stangou; Smaragdi Marinaki; Konstantinos Tziomalos
Journal:  Int J Mol Sci       Date:  2021-10-17       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.